Research programme: Immunological disease therapies - Viracta Therapeutics
Alternative Names: Immunological disease therapies research programme - Viracta TherapeuticsLatest Information Update: 02 Mar 2021
At a glance
- Originator Sunesis Pharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 24 Feb 2021 Sunesis Pharmaceuticals has been merged with Viracta Therapeutics to form Viracta Therapeutics
- 03 Jun 2008 Discontinued - Preclinical for Immunological disorders in USA (unspecified route)
- 04 May 2007 No development reported - Preclinical for Immunological disorders in USA (unspecified route)